NovaGo Therapeutics raises CHF 10 million in a Series A financing round
News 04.03.2019 ZURICH, Switzerland, March 04, 2019 – NovaGo Therapeutics AG, a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, has closed a Series A financing round of CHF 10 million led by Pureos Bioventures and the strategic partner Neurimmune. Dr. Dominik Escher, Partner at Pureos Bioventures...